Literature DB >> 11936737

Tuberculosis in Spain: epidemiological pattern and clinical practice.

M Diez1, C Huerta, T Moreno, T Caloto, D Guerra, F Pozo, J Alcaide, C Castells, J I Cardenal, A Domínguez, P Gayoso, G Gutiérrez, M J López, F Muñoz, C Navarro, M Picó, J R Quirós, F Robles, J M Sánchez, H Vanaclocha, T Vega.   

Abstract

SETTING: Thirteen Autonomous Regions in Spain.
OBJECTIVE: To study the incidence of all forms of tuberculosis (TB) and investigate clinical practice in TB.
DESIGN: Cases of all forms of tuberculosis diagnosed in the study setting from May 1986 to April 1997 were identified though active search of different databases. Clinical and epidemiological information on cases was collected from clinical records or by interview with physicians.
RESULTS: The overall incidence of all forms of tuberculosis was 38.5/100,000 and the incidence of smear-positive disease was 13.83/100,000. Most cases (97.1%) were Spanish nationals, with rates higher in men than in women (52.7/100,000 vs. 24.87/100,000) and in groups aged 25-34 and 75 years and over (61.35/100,000 and 59.35/100,000, respectively). Disseminated forms were frequent (6.6%), and the most common risk factor was human immunodeficiency virus (HIV) infection (17.7% of cases). Hospitalisation was common (71.6%). Microbiological confirmation of diagnosis was sought for 87.7% of the cases (91.8% of pulmonary vs. 75.5% of extra-pulmonary cases), and 65.2% were culture-positive (73.8% of pulmonary vs. 39.7% of extra-pulmonary cases). HIV-infected patients were treated in almost equal proportions with three or four drugs (49.7% and 48.2%, respectively), while HIV-negative cases or those whose HIV status was unknown were usually treated with three drugs.
CONCLUSION: The epidemiological pattern of TB in Spain is different to other industrialised countries in the age distribution of cases and the proportions of foreigners and cases with HIV infection. Microbiological confirmation of diagnosis is more common in pulmonary than in extra-pulmonary disease, and treatment with four drugs more frequent in HIV-positive cases.

Entities:  

Mesh:

Year:  2002        PMID: 11936737

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  5 in total

1.  Epidemiological profile of adult patients with tuberculosis and AIDS in the state of Espírito Santo, Brazil: cross-referencing tuberculosis and AIDS databases.

Authors:  Thiago Nascimento do Prado; Antonio Luiz Caus; Murilo Marques; Ethel Leonor Maciel; Jonathan E Golub; Angélica Espinosa Miranda
Journal:  J Bras Pneumol       Date:  2011 Jan-Feb       Impact factor: 2.624

2.  Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain.

Authors:  Asuncion Diaz; Mercedes Diez; Maria Jose Bleda; Mikel Aldamiz; Miguel Camafort; Xabier Camino; Concepcion Cepeda; Asuncion Costa; Oscar Ferrero; Paloma Geijo; Jose Antonio Iribarren; Santiago Moreno; Maria Elena Moreno; Pablo Labarga; Javier Pinilla; Joseba Portu; Federico Pulido; Carmen Rosa; Juan Miguel Santamaría; Mauricio Telenti; Luis Trapiella; Monica Trastoy; Pompeyo Viciana
Journal:  BMC Infect Dis       Date:  2010-09-14       Impact factor: 3.090

3.  The changing epidemiology of tuberculosis in a Spanish tertiary hospital (1995-2013).

Authors:  Andrés González-García; Jesús Fortún; Enrique Elorza Navas; Pilar Martín-Dávila; Marta Tato; Enrique Gómez-Mampaso; Santiago Moreno
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

4.  Mannose-binding lectin promoter polymorphisms and gene variants in pulmonary tuberculosis patients from cantabria (northern Spain).

Authors:  J-Gonzalo Ocejo-Vinyals; Lucía Lavín-Alconero; Pablo Sánchez-Velasco; M-Ángeles Guerrero-Alonso; Fernando Ausín; M-Carmen Fariñas; Francisco Leyva-Cobián
Journal:  Pulm Med       Date:  2012-12-04

5.  Changes in tuberculosis in human immunodeficiency virus infected patients in a Spanish tertiary hospital (1995-2013).

Authors:  A González-García; L Carpintero; J Fortún; E Navas-Elorza; P Martín-Dávila; S Moreno
Journal:  Rev Esp Quimioter       Date:  2018-07-02       Impact factor: 1.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.